EMPOWERING THE FIGHT AGAINST CANCER
Cancer is a disease of the genome. In order to understand it, we need to understand the genomic drivers to provide personalized treatments that give patients the best chance at beating their cancer. We are committed to improving clinical insight, speed of results, and health economics through a portfolio of regulated, comprehensive tissue-based and liquid biopsy Next-Generation Sequencing (NGS) products designed to be used and scaled in laboratories and health systems worldwide.
Today, 80% of patients aren’t being tested, or aren’t being tested in the window of time that it actually makes a difference for their treatment decisions.

We are changing that.
Unlock Actionable Information
from the Genome
- BIOMARKER DISCOVERY
- CDx CO-DEVELOPMENT
- CLINICAL TRIALS
- GLOBAL PATIENT ACCESS TO IVD KITS
Personal Genome Diagnostics and Fox Chase Cancer Center Announce Partnership to Broaden Liquid Biopsy Applications in Oncology Clinical Research
Feb 22, 2021